Mycophenolate mofetil in the treatment of steroid-resistant primary focal segmental glomerulosclerosis

Journal of Nephrology

Volumn 18, Issue 4, 2005, Pages 429-432

  Tang, Sydney ^a   Ho, Yiu Wing ^b   Leung, Chung Ying ^b   Lai, Kar Neng ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNITED CHRISTIAN HOSPITAL   (Hong Kong)

Author keywords

Focal segmental glomerulosclerosis; Mycophenolate mofetil; Remission; Steroid resistance

Indexed keywords

CREATININE; DILTIAZEM; ENALAPRIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PRAZOSIN; PREDNISOLONE; STEROID;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL PROTOCOL; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DOPPLER FLOWMETRY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; NEPHROTIC SYNDROME; REMISSION; TREATMENT FAILURE;

AGED; BIOPSY; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TUBULES; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; MYCOPHENOLIC ACID; PRODRUGS; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 28244474545     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Rich AR. A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis. Bull Johns Hopkins Hosp 1957; 100: 173-86.
2. Passerini P, Ponticelli C. Treatment of focal segmental glomerulosclerosis. Curr Opin Nephrol Hypertens 2001; 10: 189-93.
3. Burgess E. Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int 1999; 70 (Suppl): S26-32.
4. Badid C, Desmouliere A, Laville M. Mycophenolate mofetil: implications for the treatment of glomerular disease. Nephrol Dial Transplant 2001; 16: 1752-6.
5. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, Briggs WA. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61: 1098-114.
6. Allison AC, Eugui EM. Purine metabolism and immuno-suppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10: 77-84.
7. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345: 1321-5.
8. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-62.
9. Bolton WK, Abdel-Rahman E. Pathogenesis of focal glomerulosclerosis. Nephron 2001; 88: 6-13.
10. Schachter AD, Strom TB: Posttransplant recurrent FSGS: molecular insights and future directions. Nephron 1999; 82: 300-5.
11. Velosa JA, Holley KE, Torres VE, Offord KP. Significance of proteinuria on the outcome of renal function in patients with focal segmental glomerulosclerosis. Mayo Clin Proc 1983; 58: 568-77.
12. Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002; 17: 2011-3.
13. Montane B, Abitbol C, Chandar J, Strauss J, Zilleruelo G. Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 2003; 18: 772-7.
14. Chitalia VC, Wells JE, Robson RA, Searle M, Lynn KL. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int 1999; 56: 2236-42.